Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00664560 · ClinicalTrials.gov registry record · Phase 3

Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis

A Phase 3 study of Osteoarthritis, sponsored by POZEN.

Completed
Registry status
Phase 3
Development phase
614
Enrollment target
1
Study location

NCT00664560 is a Phase 3 study of Osteoarthritis that has completed, run by POZEN. The registered enrollment target is 614 participants, below the 813-participant average among 135 other Osteoarthritis trials with a reported enrollment target (24% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00664560, a Phase 3 study of Osteoarthritis, has completed, sponsored by POZEN.

COMPLETED
Registry status
Phase 3
Development phase
614 participants
Enrollment target
1
Study location

Study Summary

We will evaluate the efficacy of PN400 and an active comparator in patients that have Osteoarthritis of the knee.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG PN 400 (VIMOVO)
  • DRUG celebrex
  • DRUG Rescue Antacid

Study Locations (1)

North Carolina

  • POZEN - Chapel Hill

Trial Details

FieldValue
Enrollment Target 614 participants
Start Date 2008-04
Est. Completion 2009-01
Phase Phase 3

Sponsor

POZEN

24 total trials

What the Registry Record Tells You About NCT00664560

The ClinicalTrials.gov registry entry for NCT00664560 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 614 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 813-participant average among 135 other Osteoarthritis trials with a reported enrollment target (24% lower). The listed sponsor is POZEN, which has 24 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Osteoarthritis appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.

NCT00664560 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT00664560 about?

NCT00664560 is a clinical study titled "Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis". We will evaluate the efficacy of PN400 and an active comparator in patients that have Osteoarthritis of the knee.

What is the current status of trial NCT00664560?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 614 participants. The study started on 2008-04. Estimated completion is 2009-01.

What conditions does trial NCT00664560 study?

This clinical trial studies the following conditions: Osteoarthritis.

What interventions are being tested in trial NCT00664560?

The interventions under investigation include: Placebo (DRUG), PN 400 (VIMOVO) (DRUG), celebrex (DRUG), Rescue Antacid (DRUG).

Who is sponsoring clinical trial NCT00664560?

This trial is sponsored by POZEN, which has 24 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00664560 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Osteoarthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.